Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled dose-ranging study of GIA632 in moderate to severe cutaneous lichen planus
CTR20263228Phase 2Active
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GIA632 in lichen planus (LP), sponsored by Novartis. Started Sep 2026; status: active.
02
Drugs
GIA632
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on CTR20263228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263228.